AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.

Researchers with the NYU School of Medicine and the University of Michigan identified a gene called ATDC that is necessary for the development of pancreatic cancer.

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Celgene’s Abraxane failed to hit endpoints of improving disease-free survival in a late-stage study of pancreatic cancer patients.

AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.

AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute, pancreatic cancer is relatively rare with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases.

BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.

A study published today by the Pancreatic Cancer Action Network, Perthera Inc., and colleagues in the AACR journal Clinical Cancer Research found for the first time that precision medicine can improve outcomes and provide clinically meaningful information to pancreatic cancer patients.

Merrimack Pharmaceuticals Inc. will stop developing the company’s experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.